Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.
Clara Allayous(Inserm), Célèste Lebbé(Inserm), M. Beylot‐Barry(Université de Bordeaux), A. Kowal(Université Paris Cité), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Raphaël Porcher(Hotel Dieu Hospital), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes), Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Ichrak Chami(Délégation Paris 7), Brigitte Dréno(Nantes Université)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k